Media coverage about Mirati Therapeutics (NASDAQ:MRTX) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mirati Therapeutics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 48.8595382339483 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of Mirati Therapeutics (NASDAQ MRTX) traded up $1.05 on Monday, hitting $15.05. The stock had a trading volume of 369,400 shares, compared to its average volume of 378,795. Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $16.50.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16. research analysts predict that Mirati Therapeutics will post -2.87 EPS for the current fiscal year.

MRTX has been the subject of several research reports. Jefferies Group LLC set a $5.00 target price on Mirati Therapeutics and gave the company a “hold” rating in a research report on Friday, August 4th. ValuEngine downgraded Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 7th. Leerink Swann increased their target price on Mirati Therapeutics from $7.00 to $9.00 and gave the company a “market perform” rating in a research report on Friday, September 15th. Oppenheimer Holdings, Inc. initiated coverage on Mirati Therapeutics in a research report on Monday, September 18th. They issued an “outperform” rating and a $18.00 target price for the company. Finally, Cann initiated coverage on Mirati Therapeutics in a research report on Tuesday, September 19th. They issued an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $14.14.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at

In other news, SVP Jamie Christensen sold 7,499 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00. Following the completion of the transaction, the senior vice president now directly owns 10,169 shares in the company, valued at $142,366. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 12,269 shares of company stock valued at $170,226 over the last 90 days. 5.10% of the stock is owned by corporate insiders.

Mirati Therapeutics Company Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.